Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page ! T' S% {+ ]) }3 ~
( s5 i, m: y" c$ H2 N
% R* A% r o% G6 \7 m& Z% i
Sub-category:6 U+ B/ J- i6 d9 P
Molecular Targets 6 g& U) o1 P' R% Q9 D; N
2 X' V) \ o* G- ]: ?7 N" z7 g; T# Q' a+ `
Category:- ~4 c0 y0 v" e5 I, e
Tumor Biology
+ ]& q0 D) Q$ @0 m* l, Y2 ^% f6 d; I$ K( D$ [2 H& Q* @. T
: B3 p( ?( X+ C' N5 mMeeting:9 c+ k6 W- o( F- X1 T
2011 ASCO Annual Meeting # f/ q, w/ e* d) {* N- K3 y
" b4 o* ]$ g7 @. ~8 t
, G, v- M% R4 s TSession Type and Session Title:7 t! | r! E3 z" U+ E
Poster Discussion Session, Tumor Biology
7 ]7 P0 I4 V. C& n
1 o$ V! j! D5 f( C7 `/ B8 \( e' }; ?0 [! \
Abstract No:" e) d6 Y) G9 E0 C3 o
10517 , p" }" P5 Z, _0 J: p/ i
/ B" ]6 G% B- v$ [5 j( J
& c y/ F! K5 r g( FCitation:
- V" R2 ^- c2 `" p, o _J Clin Oncol 29: 2011 (suppl; abstr 10517)
I3 { \& G6 ?* r# d4 u" a8 T/ M
( B1 s v: _7 s t0 y: {5 W1 l: X7 S3 I1 G# x. g1 h! ~
Author(s):. x6 P3 I( b7 U' f" g- Y
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China + |2 S7 w# Z: i; K7 z
6 [& [1 K- E$ H. o- `4 D: L- G& E
7 q9 Q! {4 A- V5 O$ p2 O0 a4 p
2 i6 B; w6 G6 z' s
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.3 J% x$ S/ w$ C% z( O
# h* c `8 q& s, I& b
Abstract Disclosures
5 L' j* n9 N" V3 E( {: o$ H5 ]& U1 P" `5 \1 H+ \$ m
Abstract:
6 A# ^1 s7 t) F
5 |6 x# E9 a B$ n. v! d
6 d' F" ?- h* x" U& }* }+ u2 yBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.$ t! s" f8 r. `, ^, p5 I
2 _* d7 E; o& }0 v+ d% _/ K
: W! d. M" e, K9 t0 ^, W |
显身卡
